SCHEMBL8009928

SCHEMBL8009928

COc1ccc2c(C)cc(-c3csc(C(C)C)n3)nc2c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.38
RAB9A P51151 6/20 0.35
NPC1 O15118 5/20 0.35
LMNA P02545 3/20 0.35
KDM4E B2RXH2 3/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 5/20 0.34
KMT2A Q03164 4/20 0.34
NQO2 P16083 2/20 0.33
CYP19A1 P11511 1/20 0.33
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
ALDH1A1 P00352 4/20 0.32
GAA P10253 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
USP2 O75604 1/20 0.32
TP53 P04637 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8005202 0.88 RAB9A (0.37) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL8002646 0.87 SLC2A1 (0.36) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL8003707 0.86 RAB9A (0.36) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL22110048 0.79 ALDH1A1 (0.47) MAPTLMNAKDM4EMEN1KMT2A
SCHEMBL577146 0.77 MAPT (0.36) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL8011476 0.77 MEN1 (0.36) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL11951314 0.76 ALDH1A1 (0.37) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL1952194 0.75 ALDH1A1 (0.36) MAPTRAB9ANPC1LMNAKDM4E
SCHEMBL15216113 0.75 KDM4E (0.42) MAPTLMNAKDM4ENPSR1L3MBTL1
SCHEMBL15578481 0.74 TYR (0.42) MAPTRAB9ANPC1LMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009099596-A2 MACROCYCLIC SERINE PROTEASE INHIBITORS IDENIX PHARAMACEUTICALS, INC. (US) 2009-08-13 WO disclosed